Literature DB >> 15341784

The HIF pathway as a therapeutic target.

Kirsty S Hewitson1, Christopher J Schofield.   

Abstract

Hypoxia-inducible factor (HIF) is an alpha,beta-heterodimeric transcription factor that mediates cellular responses to low oxygen concentration via the transcriptional activation of specific genes involved in both tumorogenesis and angiogenesis. Manipulation of the HIF pathway has potential use for the treatment of ischemic disease and cancer. Unlike HIF-beta, which is constitutively expressed, the levels and activity of the HIF-alpha subunit are regulated by processes involving posttranslational hydroxylation, catalyzed by Fe(II)- and 2-oxoglutarate-dependent oxygenases. This review focuses on the HIF pathway as a therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15341784     DOI： 10.1016/S1359-6446(04)03202-7

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  56 in total

1.  Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1.

Authors:  Kenneth K W To; L Eric Huang
Journal:  J Biol Chem       Date:  2005-09-12       Impact factor: 5.157

Review 2.  Cellular oxygen sensing in health and disease.

Authors:  David R Mole; Peter J Ratcliffe
Journal:  Pediatr Nephrol       Date:  2007-10-23       Impact factor: 3.714

3.  Ritonavir inhibits HIF-1α-mediated VEGF expression in retinal pigment epithelial cells in vitro.

Authors:  R K Vadlapatla; A D Vadlapudi; D Pal; M Mukherji; A K Mitra
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

Review 4.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

5.  Targeting angiogenesis in melanoma: prospects for the future.

Authors:  P G Corrie; B Basu; K Ahmad Zaki
Journal:  Ther Adv Med Oncol       Date:  2010-11       Impact factor: 8.168

6.  RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.

Authors:  Martijn van Hagen; René M Overmeer; Sharareh S Abolvardi; Alfred C O Vertegaal
Journal:  Nucleic Acids Res       Date:  2009-12-21       Impact factor: 16.971

7.  A chemical approach to myocardial protection and regeneration.

Authors:  Marco Piccoli; Federica Cirillo; Guido Tettamanti; Luigi Anastasia
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

8.  Hyperoxia attenuates the inhibitory effect of nitric oxide donors on HIF prolyl-4-hydroxylase-2: Implication on discriminative effect of nitric oxide on HIF prolyl-4-hydroxylase-2 and collagen prolyl-4-hydroxylase.

Authors:  Soohwan Yum; Jeongyoun Choi; Sungchae Hong; Myung Hee Park; Jaewon Lee; Nam-Chul Ha; Yunjin Jung
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

9.  O2 Activation by Nonheme FeII α-Ketoglutarate-Dependent Enzyme Variants: Elucidating the Role of the Facial Triad Carboxylate in FIH.

Authors:  Shyam R Iyer; Vanessa D Chaplin; Michael J Knapp; Edward I Solomon
Journal:  J Am Chem Soc       Date:  2018-09-10       Impact factor: 15.419

10.  Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins.

Authors:  Matthew E Cockman; James D Webb; Holger B Kramer; Benedikt M Kessler; Peter J Ratcliffe
Journal:  Mol Cell Proteomics       Date:  2008-10-20       Impact factor: 5.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.